Novocure Stock Price, News & Analysis (NASDAQ:NVCR)

$19.30 -1.30 (-6.31 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$19.30
Today's Range$19.20 - $21.13
52-Week Range$6.75 - $24.15
Volume1.60 million shs
Average Volume983,144 shs
Market Capitalization$1.62 billion
P/E Ratio-17.71
Dividend YieldN/A
BetaN/A

About Novocure (NASDAQ:NVCR)

Novocure logoNovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:NVCR
CUSIPN/A
Phone+44-1534-756700

Debt

Debt-to-Equity Ratio0.83%
Current Ratio5.90%
Quick Ratio5.30%

Price-To-Earnings

Trailing P/E Ratio-17.7064220183486
Forward P/E Ratio-53.61
P/E GrowthN/A

Sales & Book Value

Annual Sales$177.03 million
Price / Sales9.80
Cash FlowN/A
Price / CashN/A
Book Value$1.64 per share
Price / Book11.77

Profitability

Trailing EPS($1.09)
Net Income$-131,840,000.00
Net Margins-34.83%
Return on Equity-50.94%
Return on Assets-23.60%

Miscellaneous

Employees460
Outstanding Shares89,880,000

Novocure (NASDAQ:NVCR) Frequently Asked Questions

What is Novocure's stock symbol?

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

How were Novocure's earnings last quarter?

Novocure Ltd (NASDAQ:NVCR) issued its earnings results on Thursday, February, 22nd. The medical equipment provider reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. The medical equipment provider had revenue of $53.66 million for the quarter, compared to analyst estimates of $53.17 million. Novocure had a negative net margin of 34.83% and a negative return on equity of 50.94%. The company's revenue for the quarter was up 77.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.26) EPS. View Novocure's Earnings History.

When will Novocure make its next earnings announcement?

Novocure is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Novocure.

Where is Novocure's stock going? Where will Novocure's stock price be in 2018?

7 equities research analysts have issued 12 month target prices for Novocure's shares. Their forecasts range from $14.00 to $34.00. On average, they anticipate Novocure's stock price to reach $21.29 in the next twelve months. View Analyst Ratings for Novocure.

What are Wall Street analysts saying about Novocure stock?

Here are some recent quotes from research analysts about Novocure stock:

  • 1. Mizuho analysts commented, "We therefore priced this potential upside and raise our PT to $28. KeyPoints 4Q and 2017 Results. Novocure reported 4Q17 and full-year results yesterday morning. 4Q17 revenue of $53.7 mil and 2017 revenue of $177 mil were as expected following preliminary results in January. 4Q17 EPS of $(0.12) slightly beat FactSet consensus estimate of $(0.13). CMS Reimbursement of Optune Could Materialize in 2018. With strong OS benefit demonstrated in GBM and reimbursement from private payors that cover more than 200 million lives secured in the US and government payment from other developed countries, we believe obtaining CMS reimbursement is not an if" but rather, a when" question. In that respect, we assume CMS coverage will be effective Q4, 2018 and raise our price target to $28. More recently, in December 2017, Novocure received reimbursement approval in Japan for the treatment of newly diagnosed glioblastoma (GBM)." (2/23/2018)
  • 2. According to Zacks Investment Research, "NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. " (1/13/2018)
  • 3. JPMorgan Chase & Co. analysts commented, "NVCR’s 1Q report (slides here) was largely uneventful as the co continues to make progress with the Optune launch. 1Q net revenues were $35M vs. consensus of $41M (though we note the cash vs. accrual accounting makes net revenue hard to predict). There were 1,266 active patients on therapy at 1Q-end (+16% q/q), ahead of our 1,226 estimate. We are encouraged by the progress here, though will be looking for momentum to continue to build following recent reimbursement wins, NCCN guidelines, as well as impressive follow-up survival data from the pivotal EF-14 trial." (5/1/2017)

Who are some of Novocure's key competitors?

Who are Novocure's key executives?

Novocure's management team includes the folowing people:

  • William F. Doyle, Executive Chairman of the Board (Age 54)
  • Asaf Danziger, Chief Executive Officer, Director (Age 50)
  • Kinyip Gabriel Leung, Vice Chairman of the Board (Age 53)
  • Yoram Palti M.D., Ph.D., Founder, Director (Age 78)
  • Wilhelmus C. M. Groenhuysen, Chief Financial Officer (Age 59)
  • Michael J. Ambrogi, Chief Operating Officer (Age 53)
  • Eilon D. Kirson M.D., Ph.D., Chief Science Officer and Head of Research and Development (Age 48)
  • Todd Longsworth, General Counsel (Age 42)
  • William T. Burkoth, Independent Director (Age 40)
  • Louis J. Lavigne Jr., Independent Director (Age 69)

Who owns Novocure stock?

Novocure's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.26%), Farallon Capital Management LLC (1.30%), Frontier Capital Management Co. LLC (1.21%), Tamarack Advisers LP (1.18%), Peregrine Capital Management LLC (0.97%) and Allianz Asset Management GmbH (0.60%). Company insiders that own Novocure stock include Asaf Danziger, Eilon D Kirson, Gert L Perlhagen, Michael J Ambrogi, Pomona Capital Vii Fund Invest, Robert J Mylod Jr, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and Yoram Palti. View Institutional Ownership Trends for Novocure.

Who sold Novocure stock? Who is selling Novocure stock?

Novocure's stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Jane Street Group LLC, BlackRock Inc., C WorldWide Group Holding A S, Castleark Management LLC, TIAA CREF Investment Management LLC, SG Americas Securities LLC and Rhumbline Advisers. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Eilon D Kirson, Michael J Ambrogi, Pomona Capital Vii Fund Invest, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen and Yoram Palti. View Insider Buying and Selling for Novocure.

Who bought Novocure stock? Who is buying Novocure stock?

Novocure's stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Tamarack Advisers LP, Allianz Asset Management GmbH, Renaissance Technologies LLC, Frontier Capital Management Co. LLC, Peregrine Capital Management LLC, Deutsche Bank AG and Cortina Asset Management LLC. Company insiders that have bought Novocure stock in the last two years include Asaf Danziger, Gert L Perlhagen and Robert J Mylod Jr. View Insider Buying and Selling for Novocure.

How do I buy Novocure stock?

Shares of Novocure can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novocure's stock price today?

One share of Novocure stock can currently be purchased for approximately $19.30.

How big of a company is Novocure?

Novocure has a market capitalization of $1.62 billion and generates $177.03 million in revenue each year. The medical equipment provider earns $-131,840,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. Novocure employs 460 workers across the globe.

How can I contact Novocure?

Novocure's mailing address is Le Masurier House, La Rue Le Masurier, SAINT HELIER, JE2 4YE, Jersey. The medical equipment provider can be reached via phone at +44-1534-756700 or via email at [email protected]


MarketBeat Community Rating for Novocure (NVCR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  198 (Vote Outperform)
Underperform Votes:  181 (Vote Underperform)
Total Votes:  379
MarketBeat's community ratings are surveys of what our community members think about Novocure and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Novocure (NASDAQ:NVCR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.862.862.83
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.29$20.86$20.86$19.33
Price Target Upside: 6.56% upside6.41% upside10.36% upside6.52% upside

Novocure (NASDAQ:NVCR) Consensus Price Target History

Price Target History for Novocure (NASDAQ:NVCR)

Novocure (NASDAQ:NVCR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2018Deutsche BankLower Price TargetHold -> Hold$22.00 -> $19.00HighView Rating Details
2/23/2018MizuhoReiterated RatingBuy -> Buy$25.00 -> $28.00HighView Rating Details
11/20/2017JPMorgan Chase & Co.Reiterated RatingBuyN/AView Rating Details
10/27/2017WedbushReiterated RatingOutperform$29.00 -> $25.00N/AView Rating Details
5/24/2017Wells Fargo & CoUpgradeMarket Perform -> Outperform$15.00HighView Rating Details
4/18/2017AegisReiterated RatingBuy$14.00LowView Rating Details
4/4/2017JMP SecuritiesReiterated RatingOutperform$34.00HighView Rating Details
7/29/2016BarclaysLower Price TargetUnderweight$12.00 -> $9.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Novocure (NASDAQ:NVCR) Earnings History and Estimates Chart

Earnings by Quarter for Novocure (NASDAQ:NVCR)

Novocure (NASDAQ NVCR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2018        
2/22/2018Before Market($0.14)($0.12)$53.17 million$53.66 millionViewListenView Earnings Details
10/26/20179/30/2017($0.20)($0.13)$43.45 million$50.10 millionViewN/AView Earnings Details
7/27/20176/30/2017($0.23)($0.24)$42.20 million$38.38 millionViewN/AView Earnings Details
4/27/20173/31/2017($0.25)($0.21)$39.46 million$34.88 millionViewN/AView Earnings Details
2/23/2017Q416($0.39)($0.26)$26.95 million$30.20 millionViewN/AView Earnings Details
11/2/2016Q3 2016($0.42)($0.39)$21.65 million$21.67 millionViewN/AView Earnings Details
7/28/2016Q216($0.37)($0.48)$15.90 million$17.90 millionViewListenView Earnings Details
5/9/2016Q116($0.33)($0.42)$23.65 million$13.10 millionViewN/AView Earnings Details
2/29/2016Q4 2015($0.32)$2.54$17.85 million$12.38 millionViewN/AView Earnings Details
10/26/2015Q315($2.09)$4.37 million$8.95 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Novocure (NASDAQ:NVCR) Earnings Estimates

2018 EPS Consensus Estimate: ($0.67)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.11)($0.11)($0.11)
Q2 20181($0.15)($0.15)($0.15)
Q3 20181($0.19)($0.19)($0.19)
Q4 20181($0.22)($0.22)($0.22)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Novocure (NASDAQ:NVCR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Novocure (NASDAQ NVCR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.70%
Institutional Ownership Percentage: 44.15%
Insider Trades by Quarter for Novocure (NASDAQ:NVCR)
Insider Trades by Quarter for Novocure (NASDAQ:NVCR)

Novocure (NASDAQ NVCR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/29/2018Asaf DanzigerCEOSell13,974$24.02$335,655.48356,790View SEC Filing  
1/29/2018Todd Christopher LongsworthGeneral CounselSell11,630$24.00$279,120.0016,628View SEC Filing  
1/24/2018Asaf DanzigerCEOSell20,848$22.10$460,740.80387,820View SEC Filing  
1/16/2018Asaf DanzigerCEOSell14,900$22.20$330,780.00398,068View SEC Filing  
1/12/2018Asaf DanzigerCEOSell336,420$22.33$7,512,258.60435,863View SEC Filing  
1/11/2018Eilon D KirsonInsiderSell25,320$22.00$557,040.003,181View SEC Filing  
1/9/2018Wilhelmus Cm GroenhuysenCFOSell31,132$21.02$654,394.64240,210View SEC Filing  
1/4/2018Wilhelmus Cm GroenhuysenCFOSell28,868$21.03$607,094.04268,568View SEC Filing  
11/13/2017Yoram PaltiInsiderSell30,000$17.13$513,900.00View SEC Filing  
11/9/2017Yoram PaltiCTOSell30,000$18.25$547,500.00View SEC Filing  
11/7/2017Yoram PaltiInsiderSell60,000$21.06$1,263,600.00View SEC Filing  
11/6/2017Asaf DanzigerCEOSell6,919$22.00$152,218.00View SEC Filing  
11/3/2017Asaf DanzigerCEOSell2,300$22.00$50,600.00756,024View SEC Filing  
11/3/2017Eilon D KirsonInsiderSell3,400$22.00$74,800.0040,701View SEC Filing  
11/3/2017Michael J AmbrogiCOOSell1,200$22.00$26,400.0024,987View SEC Filing  
11/2/2017Yoram PaltiCTOSell30,000$21.78$653,400.00View SEC Filing  
11/1/2017Asaf DanzigerCEOSell15,866$22.01$349,210.66774,040View SEC Filing  
11/1/2017Eilon D KirsonInsiderSell22,269$22.01$490,140.6963,120View SEC Filing  
11/1/2017Michael J AmbrogiCOOSell24,327$22.01$535,437.2749,514View SEC Filing  
9/25/2017Asaf DanzigerCEOSell900$22.05$19,845.00774,190View SEC Filing  
9/14/2017Asaf DanzigerCEOSell37,272$22.01$820,356.72776,862View SEC Filing  
9/13/2017Asaf DanzigerCEOSell35,500$22.01$781,355.00776,862View SEC Filing  
7/11/2017Asaf DanzigerCEOSell7,383$19.95$147,290.85462,765View SEC Filing  
7/10/2017Asaf DanzigerCEOSell274,359$18.07$4,957,667.13668,865View SEC Filing  
7/6/2017Asaf DanzigerCEOSell160,138$18.14$2,904,903.32899,462View SEC Filing  
7/5/2017Asaf DanzigerCEOSell155,088$18.14$2,813,296.32899,462View SEC Filing  
6/26/2017Pomona Capital Vii Fund InvestMajor ShareholderSell1,072,532$17.35$18,608,430.20View SEC Filing  
6/21/2017Eilon D KirsonInsiderSell66,361$16.78$1,113,537.58222,722View SEC Filing  
6/19/2017Asaf DanzigerCEOSell124,720$15.51$1,934,407.20896,917View SEC Filing  
6/19/2017Eilon D KirsonInsiderSell15,000$15.06$225,900.00289,083View SEC Filing  
6/16/2017Asaf DanzigerCEOSell42,457$15.15$643,223.551,030,849View SEC Filing  
6/14/2017Asaf DanzigerCEOSell94,102$15.22$1,432,232.441,069,496View SEC Filing  
6/12/2017Asaf DanzigerCEOSell180,601$15.13$2,732,493.131,163,296View SEC Filing  
6/12/2017Eilon D KirsonInsiderSell20,956$15.03$314,968.68319,083View SEC Filing  
6/5/2017Yoram PaltiInsiderSell3,825$13.82$52,861.50View SEC Filing  
6/2/2017Yoram PaltiInsiderSell8,000$13.27$106,160.007,825View SEC Filing  
5/31/2017Yoram PaltiInsiderSell8,000$12.49$99,920.0015,825View SEC Filing  
5/26/2017Yoram PaltiInsiderSell8,000$12.88$103,040.0023,825View SEC Filing  
5/24/2017Yoram PaltiInsiderSell4,000$13.15$52,600.0029,256View SEC Filing  
5/23/2017Yoram PaltiInsiderSell8,000$11.73$93,840.0035,825View SEC Filing  
5/19/2017Yoram PaltiInsiderSell8,000$11.39$91,120.0043,825View SEC Filing  
5/17/2017Yoram PaltiInsiderSell4,000$11.47$45,880.0047,825View SEC Filing  
5/16/2017Yoram PaltiInsiderSell8,000$12.05$96,400.0055,825View SEC Filing  
5/12/2017Yoram PaltiInsiderSell8,000$11.79$94,320.0063,825View SEC Filing  
5/10/2017Yoram PaltiInsiderSell8,000$12.29$98,320.0071,825View SEC Filing  
5/8/2017Yoram PaltiInsiderSell8,000$11.82$94,560.0079,825View SEC Filing  
5/4/2017Yoram PaltiInsiderSell8,000$11.42$91,360.0087,825View SEC Filing  
5/2/2017Yoram PaltiInsiderSell8,000$11.64$93,120.0095,825View SEC Filing  
4/28/2017Yoram PaltiInsiderSell8,000$11.25$90,000.00103,825View SEC Filing  
4/26/2017Yoram PaltiInsiderSell8,000$10.78$86,240.00111,825View SEC Filing  
4/24/2017Yoram PaltiInsiderSell8,000$11.26$90,080.00119,825View SEC Filing  
4/20/2017Yoram PaltiInsiderSell8,000$11.24$89,920.00127,825View SEC Filing  
4/18/2017Yoram PaltiInsiderSell16,000$10.64$170,240.00143,825View SEC Filing  
4/17/2017Yoram PaltiCTOSell4,000$10.77$43,080.00143,825View SEC Filing  
4/13/2017Yoram PaltiCTOSell4,000$10.43$41,720.00143,825View SEC Filing  
4/12/2017Yoram PaltiCTOSell4,000$10.72$42,880.00143,825View SEC Filing  
3/14/2017Gert L PerlhagenDirectorBuy125,000$6.93$866,250.006,125,000View SEC Filing  
12/22/2016Michael J AmbrogiCOOSell27,500$8.27$227,425.00139,084View SEC Filing  
12/20/2016Michael J AmbrogiCOOSell20,000$8.62$172,400.00179,084View SEC Filing  
12/19/2016Michael J AmbrogiCOOSell20,000$8.76$175,200.00179,084View SEC Filing  
12/16/2016Michael J AmbrogiCOOSell40,000$8.93$357,200.00219,084View SEC Filing  
12/14/2016Michael J AmbrogiCOOSell40,000$8.97$358,800.00259,084View SEC Filing  
12/12/2016Michael J AmbrogiCOOSell15,000$9.01$135,150.00289,084View SEC Filing  
12/8/2016Michael J AmbrogiCOOSell10,000$8.30$83,000.00299,084View SEC Filing  
12/6/2016Michael J AmbrogiCOOSell10,000$8.24$82,400.00309,084View SEC Filing  
8/5/2016Gert L PerlhagenDirectorSell676,576$1.85$1,251,665.60676,576View SEC Filing  
6/8/2016Michael J AmbrogiCOOSell20,000$12.24$244,800.00324,084View SEC Filing  
3/3/2016Asaf DanzigerCEOBuy10,000$15.00$150,000.00933,557View SEC Filing  
3/3/2016Robert J Mylod JrDirectorBuy20,000$15.78$315,600.00148,114View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Novocure (NASDAQ NVCR) News Headlines

Source:
DateHeadline
Novocure (NVCR) PT Lowered to $19.00Novocure (NVCR) PT Lowered to $19.00
www.americanbankingnews.com - February 23 at 6:14 PM
BRIEF-Novocure Ltd Reports Qtrly Net Loss Per Ordinary Share Of $0.12BRIEF-Novocure Ltd Reports Qtrly Net Loss Per Ordinary Share Of $0.12
www.reuters.com - February 22 at 5:43 PM
Novocure Ltd. to Host Earnings CallNovocure Ltd. to Host Earnings Call
finance.yahoo.com - February 22 at 5:43 PM
Novocure (NVCR) Issues  Earnings Results, Beats Estimates By $0.02 EPSNovocure (NVCR) Issues Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - February 22 at 12:54 PM
Novocure (NVCR) Cut to "Sell" at BidaskClubNovocure (NVCR) Cut to "Sell" at BidaskClub
www.americanbankingnews.com - February 17 at 10:28 PM
Novocure (NVCR) Scheduled to Post Earnings on ThursdayNovocure (NVCR) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - February 15 at 1:44 AM
Who Really Owns NovoCure Limited (NASDAQ:NVCR)?Who Really Owns NovoCure Limited (NASDAQ:NVCR)?
finance.yahoo.com - February 14 at 8:49 AM
BRIEF-Novocure Secures New $150 Mln Non-Dilutive Term Loan FinancingBRIEF-Novocure Secures New $150 Mln Non-Dilutive Term Loan Financing
www.reuters.com - February 8 at 3:36 PM
Novocure Secures New $150 Million Non-Dilutive Term Loan FinancingNovocure Secures New $150 Million Non-Dilutive Term Loan Financing
finance.yahoo.com - February 8 at 8:05 AM
 Brokerages Anticipate Novocure Ltd (NVCR) Will Post Quarterly Sales of $53.70 Million Brokerages Anticipate Novocure Ltd (NVCR) Will Post Quarterly Sales of $53.70 Million
www.americanbankingnews.com - February 8 at 4:32 AM
-$0.14 EPS Expected for Novocure Ltd (NVCR) This Quarter-$0.14 EPS Expected for Novocure Ltd (NVCR) This Quarter
www.americanbankingnews.com - February 6 at 3:16 PM
Novocure Ltd (NVCR) Given Average Recommendation of "Buy" by AnalystsNovocure Ltd (NVCR) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 6 at 10:40 AM
Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent DirectorMinerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director
finance.yahoo.com - February 5 at 8:33 AM
Novocure (NVCR) Stock Rating Upgraded by ValuEngineNovocure (NVCR) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - February 4 at 7:40 PM
JAMA Oncology Publishes EF-14 Pivotal Trial Analysis Showing Optune Plus Temozolomide Improved Survival without Negatively Influencing Health-Related Quality of Life Compared to Temozolomide Alone in Newly Diagnosed GBM PatientsJAMA Oncology Publishes EF-14 Pivotal Trial Analysis Showing Optune Plus Temozolomide Improved Survival without Negatively Influencing Health-Related Quality of Life Compared to Temozolomide Alone in Newly Diagnosed GBM Patients
finance.yahoo.com - February 1 at 3:36 PM
Todd Christopher Longsworth Sells 11,630 Shares of Novocure Ltd (NVCR) StockTodd Christopher Longsworth Sells 11,630 Shares of Novocure Ltd (NVCR) Stock
www.americanbankingnews.com - January 31 at 6:38 PM
Insider Selling: Novocure Ltd (NVCR) CEO Sells 13,974 Shares of StockInsider Selling: Novocure Ltd (NVCR) CEO Sells 13,974 Shares of Stock
www.americanbankingnews.com - January 31 at 6:24 PM
Novocure (NVCR) Downgraded to "Hold" at BidaskClubNovocure (NVCR) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - January 28 at 7:52 AM
FY2017 EPS Estimates for Novocure Ltd Raised by Wedbush (NVCR)FY2017 EPS Estimates for Novocure Ltd Raised by Wedbush (NVCR)
www.americanbankingnews.com - January 26 at 6:30 AM
Novocure Ltd (NVCR) CEO Sells $460,740.80 in StockNovocure Ltd (NVCR) CEO Sells $460,740.80 in Stock
www.americanbankingnews.com - January 25 at 9:28 PM
Quotidian Technical Highlights on Selected Medical Equipment Stocks -- Accuray, K2M Group, NuVasive, and NovoCure - PR Newswire (press release)Quotidian Technical Highlights on Selected Medical Equipment Stocks -- Accuray, K2M Group, NuVasive, and NovoCure - PR Newswire (press release)
www.prnewswire.com - January 19 at 11:53 AM
Commit To Buy NovoCure At $15, Earn 14.8% Annualized Using OptionsCommit To Buy NovoCure At $15, Earn 14.8% Annualized Using Options
www.nasdaq.com - January 18 at 4:03 PM
Insider Selling: Novocure Ltd (NVCR) CEO Sells 14,900 Shares of StockInsider Selling: Novocure Ltd (NVCR) CEO Sells 14,900 Shares of Stock
www.americanbankingnews.com - January 17 at 7:04 PM
Novocure Ltd (NVCR) CEO Asaf Danziger Sold $7.5 million of SharesNovocure Ltd (NVCR) CEO Asaf Danziger Sold $7.5 million of Shares
finance.yahoo.com - January 17 at 10:17 AM
Insider Selling: Novocure Ltd (NVCR) Insider Sells 25,320 Shares of StockInsider Selling: Novocure Ltd (NVCR) Insider Sells 25,320 Shares of Stock
www.americanbankingnews.com - January 16 at 7:08 PM
Insider Selling: Novocure Ltd (NVCR) CEO Sells 336,420 Shares of StockInsider Selling: Novocure Ltd (NVCR) CEO Sells 336,420 Shares of Stock
www.americanbankingnews.com - January 16 at 6:36 PM
Novocure (NVCR) Rating Increased to Buy at BidaskClubNovocure (NVCR) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - January 13 at 1:20 PM
Novocure (NVCR) Lowered to Hold at Zacks Investment ResearchNovocure (NVCR) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 13 at 9:26 AM
Novocure Ltd (NVCR) Given Average Rating of "Buy" by BrokeragesNovocure Ltd (NVCR) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 12 at 7:48 AM
Insider Selling: Novocure Ltd (NVCR) CFO Sells 31,132 Shares of StockInsider Selling: Novocure Ltd (NVCR) CFO Sells 31,132 Shares of Stock
www.americanbankingnews.com - January 10 at 6:48 PM
Here's Why NovoCure Popped 157% in 2017Here's Why NovoCure Popped 157% in 2017
finance.yahoo.com - January 9 at 4:36 PM
Novocure Announces Fourth Quarter and Full Year 2017 Operating Statistics and Preliminary RevenueNovocure Announces Fourth Quarter and Full Year 2017 Operating Statistics and Preliminary Revenue
finance.yahoo.com - January 9 at 10:18 AM
Wilhelmus Cm Groenhuysen Sells 28,868 Shares of Novocure Ltd (NVCR) StockWilhelmus Cm Groenhuysen Sells 28,868 Shares of Novocure Ltd (NVCR) Stock
www.americanbankingnews.com - January 5 at 6:32 PM
Novocure Ltd (NVCR) Expected to Post Quarterly Sales of $52.92 MillionNovocure Ltd (NVCR) Expected to Post Quarterly Sales of $52.92 Million
www.americanbankingnews.com - January 5 at 1:04 AM
Novocure Ltd (NVCR) Expected to Announce Earnings of -$0.14 Per ShareNovocure Ltd (NVCR) Expected to Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - January 3 at 9:44 PM
Novocure (NVCR) Rating Increased to Buy at Zacks Investment ResearchNovocure (NVCR) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - January 3 at 2:42 PM
ValuEngine Upgrades Novocure (NVCR) to HoldValuEngine Upgrades Novocure (NVCR) to Hold
www.americanbankingnews.com - January 1 at 3:10 PM
Is NovoCure Limited’s (NASDAQ:NVCR) Balance Sheet Strong Enough To Weather A Storm?Is NovoCure Limited’s (NASDAQ:NVCR) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - December 22 at 10:32 AM
Novocure to Participate in 36th Annual J.P. Morgan Healthcare ConferenceNovocure to Participate in 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 20 at 10:28 AM
 Brokerages Expect Novocure Ltd (NVCR) Will Announce Quarterly Sales of $52.92 Million Brokerages Expect Novocure Ltd (NVCR) Will Announce Quarterly Sales of $52.92 Million
www.americanbankingnews.com - December 20 at 9:32 AM
JAMA Publishes Final Analysis of EF-14 Phase 3 Pivotal Trial of Optune® Together with Temozolomide Demonstrating Unprecedented Survival Results for Newly Diagnosed GlioblastomaJAMA Publishes Final Analysis of EF-14 Phase 3 Pivotal Trial of Optune® Together with Temozolomide Demonstrating Unprecedented Survival Results for Newly Diagnosed Glioblastoma
finance.yahoo.com - December 19 at 4:30 PM
BRIEF-Novocure Receives FDA IDE Approval For Its PANOVA 3 Phase 3 Pivotal Clinical Trial In Advanced Pancreatic CancerBRIEF-Novocure Receives FDA IDE Approval For Its PANOVA 3 Phase 3 Pivotal Clinical Trial In Advanced Pancreatic Cancer
www.reuters.com - December 18 at 10:47 AM
Novocure Receives FDA IDE Approval for its PANOVA 3 Phase 3 Pivotal Clinical Trial in Advanced Pancreatic CancerNovocure Receives FDA IDE Approval for its PANOVA 3 Phase 3 Pivotal Clinical Trial in Advanced Pancreatic Cancer
finance.yahoo.com - December 18 at 10:47 AM
How Does NovoCure Limited’s (undefined:NVCR) EPS Growth Stack Up Against Industry Performance?How Does NovoCure Limited’s (undefined:NVCR) EPS Growth Stack Up Against Industry Performance?
finance.yahoo.com - December 13 at 4:42 PM
Minerva Neurosciences (NERV) Appoints William Doyle and Hans Peter Hasler to Board - StreetInsider.comMinerva Neurosciences (NERV) Appoints William Doyle and Hans Peter Hasler to Board - StreetInsider.com
www.streetinsider.com - December 11 at 11:05 AM
ETFs with exposure to Novocure Ltd. : December 7, 2017ETFs with exposure to Novocure Ltd. : December 7, 2017
finance.yahoo.com - December 7 at 4:48 PM
Is NovoCure Limited (NVCR) Undervalued?Is NovoCure Limited (NVCR) Undervalued?
finance.yahoo.com - December 4 at 4:32 PM
Novocure Ltd. – Value Analysis (NASDAQ:NVCR) : December 4, 2017Novocure Ltd. – Value Analysis (NASDAQ:NVCR) : December 4, 2017
finance.yahoo.com - December 4 at 4:32 PM
Novocure (NVCR) Receives "Buy" Rating from MizuhoNovocure (NVCR) Receives "Buy" Rating from Mizuho
www.americanbankingnews.com - December 4 at 3:46 PM
Novocure Receives Reimbursement Approval for Optune® in Japan for the Treatment of Newly Diagnosed GlioblastomaNovocure Receives Reimbursement Approval for Optune® in Japan for the Treatment of Newly Diagnosed Glioblastoma
finance.yahoo.com - December 1 at 5:40 PM

SEC Filings

Novocure (NASDAQ:NVCR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Novocure (NASDAQ:NVCR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Novocure (NASDAQ NVCR) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.